LDLR and hyperlipoproteinemia type 3: The screening of humans for APOE mutation is warranted for molecular diagnostics if the phenotype of FH is combined with hypertriglyceridemia and dysbetalipoproteinemia along with mutations of LDLR, APOB, and PCSK9 [113].